CDA | Evidence Driven
CDA | Evidence Driven

faricimab

Details

Generic Name:
faricimab
Project Status:
Pending
Therapeutic Area:
Retinal vein occlusion
Manufacturer:
Hoffmann-La Roche Limited
Call for patient/clinician input open:
Brand Name:
Vabysmo
Project Line:
Reimbursement Review
Project Number:
SR0832-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of macular edema secondary to retinal vein occlusion (RVO).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of macular edema secondary to retinal vein occlusion (RVO).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : April 22, 2024